BeiGene deal with Amgen includes $2.7 billion investment for 20.5% stake

1 November 2019

Having closed Wednesday regular trading down marginally on Thursday, China’s BeiGene (Nasdaq: BGNE) shot up 22.9% to $170.00 in after-trading as it announced a strategic collaboration with US biotech giant Amgen (Nasdaq: AMGN) under which the companies will collaborate on (i) the commercialization of Amgen’s oncology products Xgeva (denosumab), Kyprolis (carfilzomib) and Blincyto (blinatumomab) in China, and (ii) global development and commercialization in China of 20 Amgen clinical- and late-preclinical-stage pipeline products.

Additionally, Amgen will acquire a 20.5% post-closing equity stake in BeiGene at a 36% premium to the 30-day volume weighted average price of the company’s American Depositary Shares on the Nasdaq as of October 30, 2019, for a total of around $2.7 billion, valuing the Chinese biotech at around $13.5 billion.

The transactions have been approved by the boards of directors of both companies and are expected to close in the first quarter of 2020, subject to approval by a majority vote of the company’s shareholders and other standard conditions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK